. Author manuscript; available in PMC: 2018 Nov 1.

Published in final edited form as: J Am Acad Dermatol. 2017 Sep 14;77(5):902–910.e2. doi: 10.1016/j.jaad.2017.06.044

Table 1.

Incidence of all-grade pigmentary changes with approved targeted agents in monotherapy.

Drug	Primary molecular targets	Incidence of all-grade pigmentary changes (95% CI)
Drug	Primary molecular targets	Skin	Hair
Cabozantinib³⁹	VEGF-R1/-R2/-R3, Flt-3, MET, RET, KIT, AXL, TRKB, TEK, TIE-2	Not yet reported	33.6% (27.6%–40.2%)
Imatinib¹¹	BCR-ABL, PDGFR-α/β, KIT	23.0% (14.8%–33.9%)	Not yet reported
Ipilimumab^12,35–36	CTLA-4	3.6% (2.3%–5.8%)	Not yet reported
Nivolumab^37–38	PD-1	8.8% (6.1%–12.7%)	Not yet reported
Pazopanib^{13–14,32,39,43–44}	VEGF-R1/-R2/-R3, PDGFR-α/β, KIT, RAF	15.6% (0.7%–83.4%)	31.7% (18.9%–48.0%)
Pembrolizumab⁴⁰	PD-1	5.6% (3.0%–10.1%)	Not yet reported
Sorafenib^15,33	VEGF-R1/-R2/-R3, PDGFR-β, KIT, RET, RAF (CRAF & BRAF)	16.1% (8.6%–28.1%)	17.6% (8.1%–34.1%)
Sunitinib^{16–31,34,41,45–46}	VEGF-R1/-R2/-R3, PDGFR, KIT, RET, CSF-1R, Flt-3	25.5% (17.0%–36.4%)	17.9% (10.5%–28.7%)